Minghao Li, Junyuan Xiang, Fang Xiao, Qianxiang Wang, Lin Liu, Yujia Huo, Chunyu Zhang, Li Deng, Jian Feng
{"title":"Advanced prediction of cardiovascular-kidney-metabolic syndrome using eight machine learning models and 24 composite indices.","authors":"Minghao Li, Junyuan Xiang, Fang Xiao, Qianxiang Wang, Lin Liu, Yujia Huo, Chunyu Zhang, Li Deng, Jian Feng","doi":"10.1186/s12872-026-06318-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to construct and validate a machine learning classifier for cross-sectionally stratifying existing cardiovascular-kidney-metabolic (CKM) syndrome stages using routine composite inflammatory, metabolic and anthropometric indices, and to interpret core driving biomarkers via SHAP analysis.</p><p><strong>Methods and results: </strong>We analyzed data from 12,106 participants from the National Health and Nutrition Examination Survey (NHANES). Among 24 initial biomarkers, 10 were selected after addressing multicollinearity and applying feature selection. Several machine learning algorithms were evaluated, with the LightGBM model demonstrating the highest performance (ROC AUC: 0.88). External validation using the China Health and Retirement Longitudinal Study (CHARLS) dataset confirmed the model's generalizability (ROC AUC: 0.84). SHapley Additive exPlanations (SHAP) analysis revealed that metabolic markers-specifically eGDR, METS_VF, TyG, and TyG_BMI-were consistently the strongest predictors across CKM stages, whereas inflammatory indicators showed more limited utility.</p><p><strong>Conclusion: </strong>Key metabolic composite indices exhibit significant associations with CKM staging and may serve as practical, clinically feasible tools for risk stratification. The model's robust performance across distinct populations (U.S. and China) supports its potential clinical utility. Further validation in diverse populations and prospective studies is needed to confirm their predictive value and translational potential.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670576/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-026-06318-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: This study aimed to construct and validate a machine learning classifier for cross-sectionally stratifying existing cardiovascular-kidney-metabolic (CKM) syndrome stages using routine composite inflammatory, metabolic and anthropometric indices, and to interpret core driving biomarkers via SHAP analysis.
Methods and results: We analyzed data from 12,106 participants from the National Health and Nutrition Examination Survey (NHANES). Among 24 initial biomarkers, 10 were selected after addressing multicollinearity and applying feature selection. Several machine learning algorithms were evaluated, with the LightGBM model demonstrating the highest performance (ROC AUC: 0.88). External validation using the China Health and Retirement Longitudinal Study (CHARLS) dataset confirmed the model's generalizability (ROC AUC: 0.84). SHapley Additive exPlanations (SHAP) analysis revealed that metabolic markers-specifically eGDR, METS_VF, TyG, and TyG_BMI-were consistently the strongest predictors across CKM stages, whereas inflammatory indicators showed more limited utility.
Conclusion: Key metabolic composite indices exhibit significant associations with CKM staging and may serve as practical, clinically feasible tools for risk stratification. The model's robust performance across distinct populations (U.S. and China) supports its potential clinical utility. Further validation in diverse populations and prospective studies is needed to confirm their predictive value and translational potential.
期刊介绍:
BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.